Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Se Hyun | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Jang, Joung Soon | - |
dc.contributor.author | Hong, Soojung | - |
dc.contributor.author | Kim, Tae-Yong | - |
dc.contributor.author | Baek, Ji Yeon | - |
dc.contributor.author | Shin, Seong Hoon | - |
dc.contributor.author | Sun, Der Sheng | - |
dc.contributor.author | Hong, Dae-Sik | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Hong, Yong Sang | - |
dc.contributor.author | Woo, In Sook | - |
dc.contributor.author | Lee, Ju-Hyun | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.date.accessioned | 2021-08-11T09:24:29Z | - |
dc.date.available | 2021-08-11T09:24:29Z | - |
dc.date.issued | 2019-09 | - |
dc.identifier.issn | 1879-4068 | - |
dc.identifier.issn | 1879-4076 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4263 | - |
dc.description.abstract | Objectives: We aimed to explore serum biomarkers for predicting survival of older patients with metastatic solid tumors who received first line palliative chemotherapy. Materials and Methods: Serum samples were prospectively collected before first-line chemotherapy at 11 academic centers in Korea. All patients were participants in a prospective cohort study of older patients with metastatic solid tumors. Serum levels of C-reactive protein (CRP), CXCL10, SIRT1, VEGF-A, activin A, C-terminal telopeptide of type I collagen (CTx), total 25-hydroxyvitamin D were measured by ELISA and interleukin-6 (IL-6), myostatin, irisin, FGF-19, FGF-21, FGF-23 by Luminex multiplex assay. Overall survival (OS) was determined. Results: Serum samples from 138 patients (median age: 75 years, range: 70-92 years) were collected from February 2014 to December 2016. During a median follow up time of 13.8 months, 73 (52.9%) patients died. Among 13 serum markers, CRP (log-rank, P = 0.009), activin A (P = 0.007), and myostatin (P = 0.047) were significantly correlated with OS in univariate analyses. Activin A (hazard ratio [HR] 2.22, 95% confidence interval [CI] 1.32-3.72; P = 0.003) and myostatin (HR 3.02, 95% CI 1.39-6.57; P = 0.005) were significantly associated with OS after adjustment for other clinical factors. In predicting early (6-month) mortality, two inflammatory markers, IL-6 and CRP, were included in the decision-tree model. Conclusion: In older patients with cancer, high serum concentrations of activin A and myostatin were predictive of poor OS. IL-6 and CRP might be useful to select older patients at risk of early mortality. These markers could be incorporated into predictive tools for clinical decision-making and warrant further investigation. (C) 2019 Elsevier Ltd. All rights reserved. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1016/j.jgo.2019.03.015 | - |
dc.identifier.scopusid | 2-s2.0-85063682877 | - |
dc.identifier.wosid | 000485208300013 | - |
dc.identifier.bibliographicCitation | Journal of Geriatric Oncology, v.10, no.5, pp 749 - 756 | - |
dc.citation.title | Journal of Geriatric Oncology | - |
dc.citation.volume | 10 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 749 | - |
dc.citation.endPage | 756 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Geriatrics & Gerontology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Geriatrics & Gerontology | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | ACTIVIN-A | - |
dc.subject.keywordPlus | CANCER INCIDENCE | - |
dc.subject.keywordPlus | UNITED-STATES | - |
dc.subject.keywordPlus | COLON-CANCER | - |
dc.subject.keywordPlus | SARCOPENIA | - |
dc.subject.keywordPlus | SIRTUINS | - |
dc.subject.keywordPlus | FRAILTY | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | LEADS | - |
dc.subject.keywordAuthor | Prognostic | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | Frailty | - |
dc.subject.keywordAuthor | Mortality | - |
dc.subject.keywordAuthor | Activin a | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.